+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Focal Segmental Glomerulosclerosis Market - Global Forecast 2026-2032- Product Image
Focal Segmental Glomerulosclerosis Market - Global Forecast 2026-2032- Product Image
Sale

Focal Segmental Glomerulosclerosis Market - Global Forecast 2026-2032

  • Report

  • 188 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 5887513
UP TO OFF until Dec 31st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Focal Segmental Glomerulosclerosis Market is projected to reach USD 2.30 Billion in 2026. It is expected to continue growing at a CAGR of 8.13%, reaching USD 3.69 Billion by 2032.

Focal segmental glomerulosclerosis (FSGS) is a clinicopathologic kidney disorder characterized by scarring in some glomeruli and only parts of affected glomerular tufts, often presenting with proteinuria, nephrotic syndrome, reduced estimated glomerular filtration rate, edema, and elevated risk of chronic kidney disease progression. The condition includes primary, genetic, secondary, and undetermined forms, making accurate diagnosis and classification essential for treatment planning. Kidney biopsy remains central to confirming FSGS lesions, while genetic testing, immunologic assessment, and longitudinal proteinuria monitoring increasingly support differential diagnosis and risk stratification. The FSGS landscape is gaining attention because unmet clinical needs remain substantial: many patients do not achieve durable proteinuria remission, corticosteroid and immunosuppressive exposure can be clinically burdensome, and recurrence after kidney transplantation is a recognized challenge, particularly in primary disease. Relevant industry themes include FSGS treatment, nephrotic syndrome management, rare kidney disease diagnostics, podocyte injury, proteinuria reduction, chronic kidney disease care pathways, kidney biopsy, genetic kidney disease, APOL1-mediated kidney disease, and precision nephrology.

Transformative Shifts in the FSGS Landscape

The FSGS landscape is being reshaped by a shift from symptom-centered management toward mechanism-informed and precision-oriented care. Historically, treatment relied heavily on supportive therapy, renin-angiotensin-aldosterone system inhibition, blood pressure control, lipid management, edema control, and selective use of corticosteroids or calcineurin inhibitors. Current clinical practice is increasingly differentiating primary FSGS from secondary adaptive forms linked to obesity, reduced nephron mass, reflux nephropathy, hypertension, sickle cell disease, viral infections, medications, and high-risk genetic variants. This distinction is transformative because immunosuppression is not appropriate for every FSGS presentation and may expose patients to avoidable toxicity when the underlying driver is secondary or genetic. Advances in nephropathology, electron microscopy interpretation, podocyte biology, APOL1 risk variant research, and biomarker development are strengthening disease characterization. In parallel, patient registries, rare disease trial networks, and proteinuria-based clinical endpoints are improving evidence generation. The broader trend is clear: FSGS care is moving toward earlier detection, validated subtype classification, kidney-protective supportive therapy, targeted clinical trial enrollment, and multidisciplinary long-term monitoring.

Cumulative Impact of Artificial Intelligence in FSGS

Artificial intelligence is beginning to influence the FSGS ecosystem through digital pathology, clinical decision support, imaging analysis, electronic health record phenotyping, and research acceleration. AI-enabled pathology tools can support quantitative assessment of glomerulosclerosis, interstitial fibrosis, tubular atrophy, and podocyte-related structural changes, helping reduce interobserver variability when paired with expert renal pathology review. Machine learning applied to longitudinal clinical data may assist in identifying patients at higher risk of rapid kidney function decline by integrating proteinuria trajectories, serum creatinine trends, blood pressure, biopsy findings, medication exposure, comorbidities, and genetic information. In drug development and translational nephrology, AI can help mine omics datasets, identify pathway signals, optimize patient stratification, and improve trial feasibility in rare kidney disease populations. However, the cumulative impact depends on rigorous validation, representative datasets, privacy-preserving data governance, transparent algorithms, and integration into clinician-led workflows. AI should be viewed as an augmenting capability rather than a diagnostic replacement, particularly because FSGS is a histologic pattern with diverse causes requiring clinical-pathologic correlation.

Key Regional Insights Across the FSGS Ecosystem

In Asia-Pacific, FSGS priorities are shaped by large chronic kidney disease burdens, expanding nephrology capacity, variable biopsy access, and growing interest in genetic kidney disease evaluation across China, India, Japan, South Korea, and Australia. APOL1-associated FSGS is less central in most Asian populations than in populations with recent African ancestry, but secondary FSGS related to metabolic disease, hypertension, and reduced nephron reserve remains clinically important. North America has strong rare kidney disease research infrastructure, advanced transplant programs, broader access to genetic testing, and high clinical trial participation, with particular attention to APOL1-mediated kidney disease in people of African ancestry and recurrence risk after transplantation. Latin America faces a dual challenge of increasing chronic kidney disease prevalence and uneven access to renal biopsy, immunosuppressive monitoring, and specialist nephrology services, while regional centers in Brazil and Mexico support growing expertise in glomerular disease care. Europe benefits from established nephrology guidelines, cross-border research collaboration, kidney registries, and structured rare disease frameworks that help standardize diagnosis and long-term follow-up. In the Middle East, FSGS management is influenced by high rates of diabetes, obesity, consanguinity-related hereditary kidney disorders, and expanding tertiary nephrology services, especially in Gulf health systems. Across Africa, access to kidney biopsy, genetic testing, dialysis, and transplantation remains uneven, yet the region is highly relevant to FSGS research because APOL1 high-risk genotypes are present in several populations with West African ancestry and are associated with increased risk of FSGS and other kidney diseases.

Key Group Insights for FSGS Stakeholders

ASEAN countries are strengthening nephrology networks while addressing heterogeneous access to kidney biopsy, chronic kidney disease screening, and immunosuppressive monitoring, making standardized FSGS diagnostic pathways a priority. In the GCC, investment in tertiary care, transplantation, and genomic medicine is increasing the ability to distinguish primary, secondary, and hereditary FSGS, particularly in settings where consanguinity and inherited renal disease are clinically relevant. The European Union supports FSGS advancement through coordinated rare disease policies, collaborative registries, clinical research harmonization, and guideline-driven nephrology practice that improves cross-country comparability of outcomes. BRICS economies combine large patient populations with rising chronic kidney disease burdens, expanding clinical research capacity, and major needs for accessible diagnostics, affordability, and early intervention; China, India, Brazil, Russia, and South Africa each contribute distinct epidemiologic and health-system considerations. G7 countries generally have mature nephrology infrastructure, stronger reimbursement pathways for advanced diagnostics, and high participation in global rare kidney disease studies, supporting evidence generation for FSGS care. NATO countries overlap substantially with high-income North American and European systems, where military and civilian health research infrastructures can support kidney disease surveillance, digital health integration, and multidisciplinary chronic disease management, although FSGS care remains primarily driven by national health policy and specialist nephrology capacity.

Key Country Insights in FSGS Care and Research

The United States is a leading center for FSGS clinical research, rare kidney disease registries, transplant nephrology, and APOL1-associated kidney disease investigation, while disparities in kidney outcomes among people of African ancestry remain a central policy and clinical concern. Canada combines universal health coverage with strong academic nephrology programs, though geography can affect access to specialized renal pathology and genetic counseling in remote areas. Mexico and Brazil face growing chronic kidney disease pressure and regional variability in access to biopsy, dialysis, transplantation, and specialist care, with Brazil maintaining significant nephrology and transplant expertise. The United Kingdom, Germany, France, Italy, and Spain benefit from established glomerular disease services, renal registries, biopsy-based diagnostics, and guideline-aligned management, while the United Kingdom and France also have strong rare disease coordination models. Russia has major nephrology capacity concentrated in urban centers, with access variability across its large geography. China is rapidly expanding nephrology research, renal pathology capacity, and chronic kidney disease programs, making it increasingly important in FSGS diagnosis and clinical study participation. India faces a high burden of chronic kidney disease drivers, including diabetes and hypertension, alongside expanding but uneven nephrology access, creating demand for cost-effective FSGS diagnostic and treatment algorithms. Japan has advanced nephrology infrastructure, widespread health screening practices, and strong biopsy-based kidney disease expertise, supporting early glomerular disease detection. Australia has robust kidney registries and transplant services, while Indigenous populations experience disproportionate kidney disease burden that shapes public health priorities. South Korea combines advanced medical technology, strong specialty care, and active chronic kidney disease management programs, supporting uptake of precision nephrology approaches.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically validated differentiation of FSGS subtypes, because primary, genetic, and secondary forms require different treatment strategies and trial designs. Investment should focus on renal pathology quality, access to electron microscopy where appropriate, genetic testing pathways, APOL1 risk assessment in relevant populations, and standardized proteinuria and kidney function monitoring. Clinical development teams should design studies that account for disease heterogeneity, background supportive therapy, baseline proteinuria, histologic chronicity, and patient-reported outcomes. Health systems should expand multidisciplinary care involving nephrologists, renal pathologists, genetic counselors, transplant specialists, dietitians, pharmacists, and primary care teams. Digital health leaders should implement validated AI tools cautiously, emphasizing explainability, bias assessment, data security, and clinician oversight. Policy stakeholders should improve equitable access to kidney biopsy, essential kidney-protective medicines, dialysis, transplantation, and rare disease referral networks. Patient engagement is also critical: education on proteinuria monitoring, blood pressure control, medication adherence, edema recognition, and clinical trial opportunities can improve continuity of care and shared decision-making.

Research Methodology

This executive summary is developed through secondary research grounded in publicly available and clinically recognized sources, including peer-reviewed nephrology literature, kidney disease guidelines, renal registry publications, transplant and chronic kidney disease datasets, rare disease research resources, and consensus statements from nephrology and pathology communities. The methodology emphasizes evidence triangulation across epidemiology, clinical practice, diagnostics, treatment pathways, regional healthcare infrastructure, and emerging technology trends. Findings are synthesized qualitatively to avoid unsupported market sizing, market share, or forecasting claims. Regional, group, and country insights are interpreted through the lenses of kidney disease burden, biopsy access, genetic testing availability, nephrology workforce maturity, transplant capacity, rare disease infrastructure, and health equity considerations. Because FSGS is a histologic pattern rather than a single uniform disease, the analysis prioritizes clinical-pathologic correlation, subtype distinction, and data-backed understanding of risk factors such as APOL1 high-risk genotypes, metabolic disease, hypertension, medication exposures, infections, and hereditary kidney disorders.

Conclusion

Focal segmental glomerulosclerosis remains a high-need kidney disease area defined by diagnostic complexity, heterogeneous causes, and meaningful risk of chronic kidney disease progression. The most important industry shift is the move toward precision nephrology: better subtype identification, improved pathology interpretation, broader use of genetic insights, and more disciplined selection of immunosuppressive or supportive treatment strategies. Artificial intelligence, digital pathology, and real-world data analytics can strengthen the FSGS ecosystem when validated responsibly and embedded into expert-led clinical workflows. Regional opportunities differ substantially, from advanced rare disease research networks in North America, Europe, Japan, South Korea, and Australia to expanding access priorities across Latin America, Africa, parts of Asia-Pacific, and the Middle East. For stakeholders across healthcare delivery, diagnostics, research, and policy, the path forward is clear: improve early recognition of proteinuria, expand equitable diagnostic access, stratify patients accurately, support clinical research participation, and align innovation with measurable kidney health outcomes.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Focal Segmental Glomerulosclerosis Market, by Drug Class
7.1. Introduction
7.2. Angiotensin Enzyme Inhibitors
7.3. Angiotensin Receptor Blockers
7.4. Corticosteroids
8. Focal Segmental Glomerulosclerosis Market, by Disease Type
8.1. Introduction
8.2. Primary Focal Segmental Glomerulosclerosis
8.3. Secondary Focal Segmental Glomerulosclerosis
8.3.1. Virus-associated FSGS
8.3.2. Drug-induced FSGS
8.3.3. Hypertension-associated FSGS
8.4. Genetic FSGS
8.4.1. Podocin Mutation-Related FSGS
8.4.2. Alpha-Actinin-4 Mutation-Related FSGS
9. Focal Segmental Glomerulosclerosis Market, by Treatment Type
9.1. Introduction
9.2. Pharmacological Therapy
9.2.1. Immunosuppressants
9.2.2. Corticosteroids
9.3. Targeted Therapy
9.3.1. SGLT2 Inhibitors
9.3.2. Endothelin Receptor Antagonists
9.4. Supportive Therapy
9.5. Biologics
9.5.1. Monoclonal
9.5.2. RNA-Based
10. Focal Segmental Glomerulosclerosis Market, by Route Of Administration
10.1. Introduction
10.2. Oral
10.3. Injectable
10.4. Intravenous
10.5. Subcutaneous
11. Focal Segmental Glomerulosclerosis Market, by Patient Type
11.1. Introduction
11.2. Pediatric
11.3. Adult
11.4. Geriatric
12. Focal Segmental Glomerulosclerosis Market, by End User
12.1. Introduction
12.2. Hospitals
12.3. Specialty Clinics
12.4. Dialysis Centers
12.5. Ambulatory Surgical Centers
12.6. Homecare Settings
12.7. Academic & Research Institutes
13. Focal Segmental Glomerulosclerosis Market, by Distribution Channel
13.1. Introduction
13.2. Offline
13.3. Online
14. Focal Segmental Glomerulosclerosis Market, by Region
14.1. Asia-Pacific
14.2. North America
14.3. Latin America
14.4. Europe
14.5. Middle East
14.6. Africa
15. Focal Segmental Glomerulosclerosis Market, by Group
15.1. ASEAN
15.2. GCC
15.3. European Union
15.4. BRICS
15.5. G7
15.6. NATO
16. Focal Segmental Glomerulosclerosis Market, by Country
16.1. United States
16.2. Canada
16.3. Mexico
16.4. Brazil
16.5. United Kingdom
16.6. Germany
16.7. France
16.8. Russia
16.9. Italy
16.10. Spain
16.11. China
16.12. India
16.13. Japan
16.14. Australia
16.15. South Korea
17. Competitive Landscape
17.1. Market Share Analysis, 2025
17.2. FPNV Positioning Matrix, 2025
17.3. Market Concentration Analysis, 2025
17.3.1. Concentration Ratio (CR)
17.3.2. Herfindahl Hirschman Index (HHI)
17.4. Recent Developments & Impact Analysis, 2025
17.5. Product Portfolio Analysis, 2025
17.6. Benchmarking Analysis, 2025
18. Company Profiles
18.1. Aldeyra Therapeutics, Inc.
18.2. Amgen Inc.
18.3. Astellas Pharma Inc.
18.4. Aurinia Pharmaceuticals Inc.
18.5. Bayer AG
18.6. Boehringer Ingelheim International GmbH
18.7. Bristol-Myers Squibb Company
18.8. CSL Limited
18.9. Dimerix Limited
18.10. Eli Lilly and Company
18.11. F. Hoffmann-La Roche Ltd
18.12. Gilead Sciences, Inc.
18.13. GSK plc
18.14. Ionis Pharmaceuticals, Inc.
18.15. Johnson & Johnson
18.16. Merck & Co., Inc.
18.17. Novartis AG
18.18. Omeros Corporation
18.19. Otsuka Pharmaceutical Co., Ltd.
18.20. Pfizer Inc.
18.21. Sanofi SA
18.22. Takeda Pharmaceutical Company Limited
18.23. Travere Therapeutics, Inc.
18.24. Vertex Pharmaceuticals Incorporated
18.25. ZyVersa Therapeutics, Inc.
List of Figures
FIGURE 1. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
FIGURE 7. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISEASE TYPE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 13. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2032 (%)
FIGURE 15. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 17. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 19. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 21. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 23. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 25. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 27. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL ANGIOTENSIN ENZYME INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL ANGIOTENSIN ENZYME INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL ANGIOTENSIN ENZYME INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL ANGIOTENSIN RECEPTOR BLOCKERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL ANGIOTENSIN RECEPTOR BLOCKERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL ANGIOTENSIN RECEPTOR BLOCKERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL SECONDARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL SECONDARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL SECONDARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL VIRUS-ASSOCIATED FSGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL VIRUS-ASSOCIATED FSGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL VIRUS-ASSOCIATED FSGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL DRUG-INDUCED FSGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL DRUG-INDUCED FSGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL DRUG-INDUCED FSGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL HYPERTENSION-ASSOCIATED FSGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL HYPERTENSION-ASSOCIATED FSGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL HYPERTENSION-ASSOCIATED FSGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL GENETIC FSGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL GENETIC FSGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL GENETIC FSGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL PODOCIN MUTATION-RELATED FSGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL PODOCIN MUTATION-RELATED FSGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL PODOCIN MUTATION-RELATED FSGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL ALPHA-ACTININ-4 MUTATION-RELATED FSGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL ALPHA-ACTININ-4 MUTATION-RELATED FSGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL ALPHA-ACTININ-4 MUTATION-RELATED FSGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL PHARMACOLOGICAL THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL PHARMACOLOGICAL THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL PHARMACOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL IMMUNOSUPPRESSANTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL IMMUNOSUPPRESSANTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL IMMUNOSUPPRESSANTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL TARGETED THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL TARGETED THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL SGLT2 INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL SGLT2 INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL SGLT2 INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL ENDOTHELIN RECEPTOR ANTAGONISTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL ENDOTHELIN RECEPTOR ANTAGONISTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL ENDOTHELIN RECEPTOR ANTAGONISTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL SUPPORTIVE THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL SUPPORTIVE THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL SUPPORTIVE THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL BIOLOGICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL MONOCLONAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL MONOCLONAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL MONOCLONAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL RNA-BASED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL RNA-BASED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL RNA-BASED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL ADULT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL ADULT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL DIALYSIS CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL DIALYSIS CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL DIALYSIS CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL ONLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 119. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 120. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 121. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 122. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY SECONDARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS, 2017-2032 (USD MILLION)
TABLE 123. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY GENETIC FSGS, 2017-2032 (USD MILLION)
TABLE 124. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 125. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PHARMACOLOGICAL THERAPY, 2017-2032 (USD MILLION)
TABLE 126. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 127. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 128. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 129. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 130. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 131. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 132. NORTH AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 133. NORTH AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 134. NORTH AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 135. NORTH AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY SECONDARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS, 2017-2032 (USD MILLION)
TABLE 136. NORTH AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY GENETIC FSGS, 2017-2032 (USD MILLION)
TABLE 137. NORTH AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 138. NORTH AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PHARMACOLOGICAL THERAPY, 2017-2032 (USD MILLION)
TABLE 139. NORTH AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 140. NORTH AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 141. NORTH AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 142. NORTH AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 143. NORTH AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 144. NORTH AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 145. LATIN AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 146. LATIN AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 147. LATIN AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 148. LATIN AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY SECONDARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS, 2017-2032 (USD MILLION)
TABLE 149. LATIN AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY GENETIC FSGS, 2017-2032 (USD MILLION)
TABLE 150. LATIN AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 151. LATIN AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PHARMACOLOGICAL THERAPY, 2017-2032 (USD MILLION)
TABLE 152. LATIN AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 153. LATIN AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 154. LATIN AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 155. LATIN AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 156. LATIN AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 157. LATIN AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 158. EUROPE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 159. EUROPE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 160. EUROPE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 161. EUROPE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY SECONDARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS, 2017-2032 (USD MILLION)
TABLE 162. EUROPE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY GENETIC FSGS, 2017-2032 (USD MILLION)
TABLE 163. EUROPE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 164. EUROPE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PHARMACOLOGICAL THERAPY, 2017-2032 (USD MILLION)
TABLE 165. EUROPE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 166. EUROPE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 167. EUROPE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 168. EUROPE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 169. EUROPE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 170. EUROPE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 171. MIDDLE EAST FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 172. MIDDLE EAST FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 173. MIDDLE EAST FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 174. MIDDLE EAST FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY SECONDARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS, 2017-2032 (USD MILLION)
TABLE 175. MIDDLE EAST FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY GENETIC FSGS, 2017-2032 (USD MILLION)
TABLE 176. MIDDLE EAST FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 177. MIDDLE EAST FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PHARMACOLOGICAL THERAPY, 2017-2032 (USD MILLION)
TABLE 178. MIDDLE EAST FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 179. MIDDLE EAST FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 180. MIDDLE EAST FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 181. MIDDLE EAST FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 182. MIDDLE EAST FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 183. MIDDLE EAST FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 184. AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 185. AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 186. AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 187. AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY SECONDARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS, 2017-2032 (USD MILLION)
TABLE 188. AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY GENETIC FSGS, 2017-2032 (USD MILLION)
TABLE 189. AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 190. AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PHARMACOLOGICAL THERAPY, 2017-2032 (USD MILLION)
TABLE 191. AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 192. AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 193. AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 194. AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 195. AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 196. AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 197. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 198. ASEAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 199. ASEAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 200. ASEAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 201. ASEAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY SECONDARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS, 2017-2032 (USD MILLION)
TABLE 202. ASEAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY GENETIC FSGS, 2017-2032 (USD MILLION)
TABLE 203. ASEAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 204. ASEAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PHARMACOLOGICAL THERAPY, 2017-2032 (USD MILLION)
TABLE 205. ASEAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 206. ASEAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 207. ASEAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 208. ASEAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 209. ASEAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 210. ASEAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 211. GCC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 212. GCC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 213. GCC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 214. GCC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY SECONDARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS, 2017-2032 (USD MILLION)
TABLE 215. GCC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY GENETIC FSGS, 2017-2032 (USD MILLION)
TABLE 216. GCC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 217. GCC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PHARMACOLOGICAL THERAPY, 2017-2032 (USD MILLION)
TABLE 218. GCC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 219. GCC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 220. GCC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 221. GCC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 222. GCC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 223. GCC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 224. EUROPEAN UNION FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 225. EUROPEAN UNION FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 226. EUROPEAN UNION FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 227. EUROPEAN UNION FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY SECONDARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS, 2017-2032 (USD MILLION)
TABLE 228. EUROPEAN UNION FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY GENETIC FSGS, 2017-2032 (USD MILLION)
TABLE 229. EUROPEAN UNION FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 230. EUROPEAN UNION FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PHARMACOLOGICAL THERAPY, 2017-2032 (USD MILLION)
TABLE 231. EUROPEAN UNION FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 232. EUROPEAN UNION FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 233. EUROPEAN UNION FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 234. EUROPEAN UNION FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 235. EUROPEAN UNION FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 236. EUROPEAN UNION FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 237. BRICS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 238. BRICS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 239. BRICS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 240. BRICS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY SECONDARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS, 2017-2032 (USD MILLION)
TABLE 241. BRICS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY GENETIC FSGS, 2017-2032 (USD MILLION)
TABLE 242. BRICS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 243. BRICS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PHARMACOLOGICAL THERAPY, 2017-2032 (USD MILLION)
TABLE 244. BRICS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 245. BRICS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 246. BRICS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 247. BRICS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 248. BRICS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 249. BRICS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 250. G7 FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 251. G7 FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 252. G7 FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 253. G7 FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY SECONDARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS, 2017-2032 (USD MILLION)
TABLE 254. G7 FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY GENETIC FSGS, 2017-2032 (USD MILLION)
TABLE 255. G7 FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 256. G7 FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PHARMACOLOGICAL THERAPY, 2017-2032 (USD MILLION)
TABLE 257. G7 FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 258. G7 FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 259. G7 FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 260. G7 FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 261. G7 FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 262. G7 FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 263. NATO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 264. NATO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 265. NATO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 266. NATO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY SECONDARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS, 2017-2032 (USD MILLION)
TABLE 267. NATO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY GENETIC FSGS, 2017-2032 (USD MILLION)
TABLE 268. NATO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 269. NATO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PHARMACOLOGICAL THERAPY, 2017-2032 (USD MILLION)
TABLE 270. NATO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 271. NATO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 272. NATO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 273. NATO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 274. NATO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 275. NATO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 276. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 277. UNITED STATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 278. UNITED STATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 279. UNITED STATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 280. UNITED STATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY SECONDARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS, 2017-2032 (USD MILLION)
TABLE 281. UNITED STATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY GENETIC FSGS, 2017-2032 (USD MILLION)
TABLE 282. UNITED STATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 283. UNITED STATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PHARMACOLOGICAL THERAPY, 2017-2032 (USD MILLION)
TABLE 284. UNITED STATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 285. UNITED STATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 286. UNITED STATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 287. UNITED STATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 288. UNITED STATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 289. UNITED STATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 290. CANADA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 291. CANADA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 292. CANADA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 293. CANADA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY SECONDARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS, 2017-2032 (USD MILLION)
TABLE 294. CANADA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY GENETIC FSGS, 2017-2032 (USD MILLION)
TABLE 295. CANADA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 296. CANADA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PHARMACOLOGICAL THERAPY, 2017-2032 (USD MILLION)
TABLE 297. CANADA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 298. CANADA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 299. CANADA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 300. CANADA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 301. CANADA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 302. CANADA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 303. MEXICO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 304. MEXICO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 305. MEXICO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 306. MEXICO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY SECONDARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS, 2017-2032 (USD MILLION)
TABLE 307. MEXICO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY GENETIC FSGS, 2017-2032 (USD MILLION)
TABLE 308. MEXICO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 309. MEXICO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PHARMACOLOGICAL THERAPY, 2017-2032 (USD MILLION)
TABLE 310. MEXICO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY TARGETED THERAPY, 2017-2032 (USD MILLION)
TABLE 311. MEXICO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 312. MEXICO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 313. MEXICO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 314. MEXICO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 315. MEXICO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 316. BRAZIL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 317. BRAZIL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 318. BRAZIL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 319. BRAZIL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY SECONDARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS, 2017-2032

Companies Mentioned

  • Aldeyra Therapeutics, Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • Aurinia Pharmaceuticals Inc.
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • CSL Limited
  • Dimerix Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences, Inc.
  • GSK plc
  • Ionis Pharmaceuticals, Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Omeros Corporation
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Travere Therapeutics, Inc.
  • Vertex Pharmaceuticals Incorporated
  • ZyVersa Therapeutics, Inc.

Table Information

Report AttributeDetails
No. of Pages188
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 2.3 Billion
Forecasted Market Value ( USD ) by 2032 $ 3.69 Billion
Compound Annual Growth Rate8.1%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Topics

Related Reports

Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Outlook 2026-2034: Market Share, and Growth Analysis by Disease Type (Primary FSGS, Secondary FSGS), Disease Management, End User - Product Image

Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Outlook 2026-2034: Market Share, and Growth Analysis by Disease Type (Primary FSGS, Secondary FSGS), Disease Management, End User

  • Report
  • 160 Pages
  • Global
From
Focal Segmental Glomerulosclerosis Drugs Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Focal Segmental Glomerulosclerosis Drugs Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Focal Segmental Glomerulosclerosis Market - A Global and Regional Analysis: Focus on Country, 2025-2035 - Product Image

Focal Segmental Glomerulosclerosis Market - A Global and Regional Analysis: Focus on Country, 2025-2035

  • Report
  • Global
From
Focal Segmental Glomerulosclerosis Market Report 2026 - Product Image

Focal Segmental Glomerulosclerosis Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Focal Segmental Glomerulosclerosis - Global Strategic Business Report - Product Image

Focal Segmental Glomerulosclerosis - Global Strategic Business Report

  • Report
  • 194 Pages
  • Global
From

About the Focal Segmental Glomerulosclerosis Market

Focal Segmental Glomerulosclerosis (FSGS) is a type of kidney disorder that affects the filtering units of the kidney, known as glomeruli. It is a leading cause of nephrotic syndrome, a condition characterized by proteinuria, edema, and hypoalbuminemia. FSGS is a major cause of end-stage renal disease (ESRD) and is associated with a high risk of progression to ESRD. Treatment of FSGS is focused on controlling the underlying cause, if possible, and managing the symptoms. Treatment options include medications, lifestyle modifications, and dialysis. The market for Liver and Kidney Disorders Drugs is expected to grow in the coming years due to the increasing prevalence of chronic kidney diseases and liver diseases. The market is driven by factors such as the increasing prevalence of diabetes, rising geriatric population, and the increasing demand for organ transplants. Companies in the Focal Segmental Glomerulosclerosis market include AstraZeneca, GlaxoSmithKline, Merck & Co., Pfizer, Sanofi, and Novartis. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.